| Study Aim |
EMERALD aims to determine the diagnostic performance and cost-effectiveness of a new form of surveillance for people with stable DMO and/or PDR, using the current standard of care as the reference standard.
The specific objectives of this study are to evaluate the new surveillance pathway to:
1. Quantify and compare the diagnostic accuracy (in terms of sensitivity, specificity, overall agreement, positive and negative likelihood ratios) of the new pathway of surveillance (ophthalmic grader pathway) using the current standard of care pathway as the reference standard. This will be done separately for DMO and PDR.
2. Assess acceptability of the new surveillance pathway.
3. Determine the proportion of patients requiring subsequent full clinical assessment by an ophthalmologist under the new pathway.
4. Determine the proportion of patients unable to undergo imaging tests, with images of inadequate quality and indeterminate findings under the new pathway.
5. Establish relative cost-effectiveness of the new surveillance pathway.
|
